Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Orion Portfolio Solutions LLC

Orion Portfolio Solutions LLC cut its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 16.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 26,072 shares of the biopharmaceutical company's stock after selling 5,041 shares during the quarter. Orion Portfolio Solutions LLC's holdings in Halozyme Therapeutics were worth $1,247,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Quantbot Technologies LP acquired a new stake in shares of Halozyme Therapeutics in the 3rd quarter valued at $150,000. HighTower Advisors LLC raised its stake in Halozyme Therapeutics by 20.2% in the third quarter. HighTower Advisors LLC now owns 36,174 shares of the biopharmaceutical company's stock valued at $2,080,000 after buying an additional 6,075 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in Halozyme Therapeutics by 6.2% during the 3rd quarter. Janus Henderson Group PLC now owns 545,173 shares of the biopharmaceutical company's stock worth $31,204,000 after buying an additional 31,871 shares during the last quarter. Stifel Financial Corp boosted its position in shares of Halozyme Therapeutics by 126.3% during the 3rd quarter. Stifel Financial Corp now owns 17,121 shares of the biopharmaceutical company's stock worth $980,000 after acquiring an additional 9,555 shares in the last quarter. Finally, EP Wealth Advisors LLC purchased a new position in shares of Halozyme Therapeutics in the 3rd quarter valued at about $357,000. Hedge funds and other institutional investors own 97.79% of the company's stock.

Remove Ads

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Wells Fargo & Company decreased their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. Benchmark restated a "buy" rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a report on Thursday, February 20th. HC Wainwright reissued a "buy" rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Finally, Piper Sandler upped their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research note on Friday, January 10th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $62.78.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO traded up $3.11 during midday trading on Wednesday, reaching $60.65. The stock had a trading volume of 2,068,251 shares, compared to its average volume of 1,404,554. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. The stock has a market cap of $7.49 billion, a P/E ratio of 17.68, a P/E/G ratio of 0.42 and a beta of 1.32. The firm has a fifty day simple moving average of $60.12 and a two-hundred day simple moving average of $54.89. Halozyme Therapeutics, Inc. has a 12-month low of $37.73 and a 12-month high of $66.00.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The firm had revenue of $298.01 million during the quarter, compared to analysts' expectations of $285.74 million. On average, equities analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of the stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $56.30, for a total value of $281,500.00. Following the completion of the transaction, the director now directly owns 38,611 shares of the company's stock, valued at approximately $2,173,799.30. This trade represents a 11.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Michael J. Labarre sold 1,697 shares of the business's stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.16. Following the sale, the senior vice president now directly owns 173,756 shares in the company, valued at $10,126,499.68. This trade represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 22,200 shares of company stock valued at $1,286,568 over the last quarter. Company insiders own 2.40% of the company's stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.